Introduction
============

Von Hippel-Lindau (VHL) disease is an autosomal dominant hereditary syndrome caused by germline mutations in the *VHL* tumor suppressor gene, which is located on chromosome 3p25-26. The clinical phenotype of VHL disease is characterized by the development of a panel of benign and malignant, highly vascularized tumors in several organ systems. One of the major clinical manifestations is clear-cell renal cell carcinoma (ccRCC). The emergence of tumors follows the inactivation of the remaining wild-type allele. Somatic *VHL* inactivation is also a hallmark of the majority of cases of sporadic ccRCC, and insights into *VHL* gene function have resulted in the use of antiangiogenic targeted therapies, which are now first line in the treatment of advanced renal tumors ([@b1-ijo-53-04-1455]). Fuhrman\'s nuclear grade is the cornerstone of the prognostic classification of ccRCC and is based on increasing nuclear size, irregularity and nucleolar prominence ([@b2-ijo-53-04-1455]).

In the last few years, numerous pan-genomic studies \[comparative genomic hybridization-array, and gene and microRNA (miRNA/miR) expression profiles\] have well characterized sporadic ccRCC ([@b3-ijo-53-04-1455]--[@b7-ijo-53-04-1455]). However, few studies have been published in the field of VHL-associated ccRCC ([@b8-ijo-53-04-1455],[@b9-ijo-53-04-1455]). Fisher *et al* demonstrated that kidney tumors developing from a germline VHL mutation exhibit complementarity of the evolutionary principles of contingency and convergence. Notably, reduced mutation burden and limited evidence of intra-tumor heterogeneity were detected in these tumors ([@b10-ijo-53-04-1455]). To the best of our knowledge, no previous study has focused on miRNA profiles in VHL-associated renal tumors compared with in sporadic ccRCC; these two entities are considered similar but no transcriptomic comparison study has been conducted to confirm this fact. The main function of miRNAs is to suppress the translation of target genes; however, they can also process mRNAs for cellular decay ([@b11-ijo-53-04-1455]). Mature miRNAs have numerous targets, are often members of the same regulatory networks, and operate in regulatory feedback loops. These properties position them as fine-tuning modulators of set points in homeostatic processes in normal cells. It has previously been reported that discrete sets of miRNAs are induced and repressed in various types of cancer, and are specific to particular diagnoses and progression patterns, and predictive of responses to treatment. In cancer, aberrations in the expression of specific miRNAs may have well-defined tumor-suppressing or oncogenic functions ([@b12-ijo-53-04-1455]). Furthermore, since a given miRNA has several targets, multiple pro-oncogenic or tumor-suppressing pathways are affected, and these pathways, in turn, regulate the miRNA expression in a feedback-loop mechanism ([@b13-ijo-53-04-1455]). Studies regarding miRNA dysregulation in cancer have risen rapidly recently, including those in sporadic ccRCC ([@b14-ijo-53-04-1455],[@b15-ijo-53-04-1455]).

The transcriptomic analysis of synchronous tumors occurring within the kidney in one patient offers a rare opportunity to investigate the evolution of tumors. In the present study, to better understand the biological processes implicated in the tumorigenesis of VHL-associated ccRCC, the transcriptomic (miRNA and mRNA) signature of VHL-associated tumors was determined using multiple tumor samples from two distinct patients who possessed several different primary kidney tumors. For comparison, the miRNA and mRNA profiles of 12 independent VHL-associated tumors were determined and were compared with the profiles of 22 sporadic renal tumors. The present study may provide information regarding the molecular pathogenesis of ccRCC in patients with VHL disease and offer possibilities for further molecular investigations.

Materials and methods
=====================

Patient samples and ethical consent
-----------------------------------

A total of 36 patients were recruited between 2002 and 2009. Their mean age at diagnosis was 54.9 years old. The sample series, which comprised two sets of 13 (from 2 patients) and 34 (from 34 patients) human ccRCC samples were obtained from the French Kidney Cancer Consortium coordinated by Professor Stéphane Richard (French National Network for Rare Cancers in Adults PREDIR Center, Bicêtre Hospital, Le Kremlin-Bicêtre, France). The present study was approved by the ethical committee of Bicêtre Hospital (Le Kremlin-Bicêtre, France). Primary tumors, and for some cases adjacent non-tumor samples, were obtained from patients who underwent surgical tumor resection. All patients provided written informed consent prior to surgery for use of their tumors. Tumor samples were frozen immediately in liquid nitrogen following surgery and were classified according to the Fuhrman nuclear grading system, after which they were grouped into low grade (grade 1+2) and high grade (grade 3+4) tumors ([@b2-ijo-53-04-1455]).

The main clinical and genetic features of the patients, and tumor characteristics, are described in [Table I](#tI-ijo-53-04-1455){ref-type="table"}. Part of the tumor series was previously reported ([@b16-ijo-53-04-1455]). Differences in the numbers of samples are due to the lack of sufficient RNA quantity.

Tumor cryosections and total RNA extraction
-------------------------------------------

All samples were frozen at −80°C prior to RNA extraction. The percentage of malignant tumor cell content was determined in the first and last sections obtained using a cryostat, and sections with \>60% malignant tumor cell content were used for subsequent experimentation (mean of all the series: 83±12%). Total RNA was isolated using TRIzol^®^ reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer\'s protocol. Nucleic acid concentration and purity were determined using NanoDrop ND-1000 (NanoDrop; Thermo Fisher Scientific, Inc., Wilmington, DE, USA), and RNA quality was verified using a 2100 Bioanalyser (Agilent Technologies, Inc., Santa Clara, CA, USA) using an RNA integrity no. \>6. The reference sample was based on a pool of RNA extracted from all normal adjacent tissues available, which consisted of 17 renal tissue samples from patients with sporadic ccRCC, and was used for all analyses.

miRNA and gene microarray expression analysis
---------------------------------------------

Each sample was prepared according to the Agilents miRNA Microarray system protocol (Agilent Technologies, Inc.). Total RNA (100 ng) was labeled and hybridized to Agilent human miRNA 8×15K microarrays v3 (AMADID 21827; Agilent Technologies, Inc.) containing 851 human and 88 human viral miRNAs, each replicated 16 times, and Agilent human genome 4×44K microarrays (Agilent Technologies, Inc.) for gene expression, according to the manufacturer\'s protocol. All processing methods used for miRNA analyses were performed on the Cy3 Median Signal in Agilent Feature software v10.7 (Agilent Technologies, Inc.). For gene expression, analyses were performed on the Cy3 and Cy5 Median signal in Agilent Feature software v10.7 (Agilent Technologies, Inc.). Raw data files were extracted using functions in Bioconductor ([@b17-ijo-53-04-1455]). Flagged spots, as well as control spots, were systematically removed, and data were log~2~ transformed. Quantile normalization was performed using the normalizeBetweenArray function from R package \'LIMMA\' (version no. 3.34.9) ([@b18-ijo-53-04-1455]). The median of each probe for a given miRNA was computed and the corresponding value was assigned to the miRNA. Data were then filtered according to the maximum number of missing values allowed for each miRNA (30%).

Hierarchical clusters were computed using the \'dist\' function from R, using the \'Euclidian\' method as a measure of distance. Hierarchical clustering was performed using the \'hclust\' function from R using the distance matrix previously computed and Ward\'s method.

To assess differentially expressed miRNAs, the fold-changes and standard errors were initially estimated between two groups of samples by fitting a linear model for each miRNA with the \'lmFit\' function of LIMMA package. Subsequently, empirical Bayes smoothing was applied to the standard errors in the linear model previously computed using the \'eBayes\' function of LIMMA. To extract a table of the top-ranked genes from the linear model fit, the topTable function in LIMMA was utilized. The results were saved in a table file format.

BRB analyses were performed to compare the tumor groups and the reference group. miRNAs and genes that were significantly differentially expressed between the groups at P\<0.05 using BRB ArrayTools v2 (<https://brb.nci.nih.gov/BRB-ArrayTools/>), as determined using two-way analysis of variance and multiple correction Benjamini-Hochberg test, were selected for further analysis. Significantly differentially expressed miRNAs were used to build a hierarchical cluster using Gene-E (<https://software.broadinstitute.org/GENE-E/index.html>). For biological interpretation of significant genes, the Database for Annotation, Visualization and Integrated Discovery (DAVID, <https://david.ncifcrf.gov/>) was employed to perform the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. Significant KEGG pathways (P\<0.05) were selected in VHL-associated and sporadic ccRCC tumors.

Results
=======

Patients and samples
--------------------

The main characteristics of the two tumor sets used in the present study and individual patient data are reported in [Table I](#tI-ijo-53-04-1455){ref-type="table"}. The first set consisted of several samples from multiple tumors obtained from two patients with VHL disease \[Patient 2203, n=6; Patient 1674, n=7 (6 for miRNA analysis and 7 for mRNA analysis)\]. The second set consisted of 12 VHL-associated renal tumors (11 for miRNA analysis and 12 for mRNA analysis) and 22 sporadic ccRCC tumors (21 for miRNA analysis and 22 for mRNA analysis) from 34 patients.

Lack of heterogeneity for miRNA and mRNA expression profiles between multiple tumors for the same patient with VHL disease
--------------------------------------------------------------------------------------------------------------------------

Patients affected with VHL disease can simultaneously develop several multifocal and bilateral tumors in the kidneys. The present study performed microarray gene and miRNA expression analyses on several samples from different tumors obtained from the same patient, for two independent patients (Patients 2203 and 1674). Firstly, unsupervised hierarchical clustering analyses were conducted on the miRNA and gene expression profiles. In both analyses, tumor samples were well separated from the normal renal tissue pool. In addition, unsupervised hierarchical clustering of the miRNA expression profiles was not able to discriminate between the two patients ([Fig. 1A](#f1-ijo-53-04-1455){ref-type="fig"}); however, unsupervised hierarchical clustering of the mRNA expression profiles was able to distinguish between the two patients; this may be explained by the different genetic background ([Fig. 1B](#f1-ijo-53-04-1455){ref-type="fig"}).

The present study also explored the differences between tumor samples and the normal reference samples, for each patient. For patient 2203, a total of 1,377 genes and 51 miRNAs were significantly differentially expressed. For patient 1674, a total of 1,282 genes and 56 miRNAs were differentially expressed ([Table II](#tII-ijo-53-04-1455){ref-type="table"}). In addition, as shown in [Fig. 2](#f2-ijo-53-04-1455){ref-type="fig"}, a hierarchical cluster analysis built with 70 dysregulated miRNAs clearly indicated separate tumor clusters from the normal reference group. No obvious differences were detected between the samples, but the two subclusters could be distinguished according to the nuclear grade of these tumors. When tumors were compared two by two, no significant difference was found, thus supporting the hypothesis of a similar molecular evolution between independent tumors. KEGG biological pathway analysis was conducted using DAVID software. This analysis globally identified three classes of pathways that were overrepresented with dysregulated genes. Notably, in the two patients, the most significant pathways were similar, and were implicated in \'immunity\' and \'metabolism\' ([Table III](#tIII-ijo-53-04-1455){ref-type="table"}).

miRNA expression levels distinguish VHL-associated tumors from sporadic ccRCC
-----------------------------------------------------------------------------

Using microarray analysis, a total of 103 miRNAs were identified as differentially expressed among the VHL-associated and sporadic ccRCC samples (fold-change \<−2 or \>2) compared with in the normal reference group ([Fig. 3](#f3-ijo-53-04-1455){ref-type="fig"}). These differentially expressed miRNAs are similar to those described in the first set of samples. Two thirds of miRNAs (12 upregulated and 56 downregulated) were common to both groups. Hierarchical cluster analysis, based on the 58 most differentially expressed miRNAs (fold-change \<-3 or \>3), revealed three clusters that mainly define VHL-associated (cluster 1) and sporadic (clusters 2 and 3) specimen profiles ([Fig. 4](#f4-ijo-53-04-1455){ref-type="fig"}). Of the 21 sporadic ccRCC samples, only two samples were allocated to the VHL-related branch. Branches 2 and 3 were able to distinguish high and low grades of sporadic ccRCC, respectively. The VHL-associated tumors formed a separate subcluster (cluster 1), thus indicating that their miRNA expression levels were different from those of sporadic tumor samples. In addition, supervised analysis directly comparing the VHL-associated and sporadic tumors (fold-change \<−1.5 or \>1.5; raw P\<0.05) identified 18 differentially expressed miRNAs ([Table IV](#tIV-ijo-53-04-1455){ref-type="table"} and [Fig. 5](#f5-ijo-53-04-1455){ref-type="fig"}). Taken together, these analyses indicated that, even though some differentially expressed miRNAs were similar between the two tumor groups, it was possible to distinguish between these two groups.

Transcriptomic analyses identify biological pathways involved in VHL-associated tumors
--------------------------------------------------------------------------------------

Transcriptomic analysis was performed to identify genes exhibiting altered expression in renal VHL-associated tumors. mRNA profiles from VHL-associated and sporadic ccRCC groups were compared with the normal renal tissue pool. Similar to the findings of the miRNA analysis, few differences in mRNA expression profiles were detected between the two series of ccRCC. Notably, 3,489 (1,563 up- and 1,926 downregulated) and 3,059 (1,218 up- and 1,841 downregulated) genes were dysregulated in VHL-related tumors and sporadic ccRCC, respectively, compared with in the normal renal tissue pool. A total of 2,474 genes (959 up- and 1515 downregulated) were found in common between the groups, representing 71 and 81% of each signature, respectively ([Fig. 6](#f6-ijo-53-04-1455){ref-type="fig"}). Dysregulated pathways were similar to those previously described for the first set of samples ([Table III](#tIII-ijo-53-04-1455){ref-type="table"}).

Discussion
==========

The present study detected differentially expressed mRNAs and miRNAs in VHL-associated ccRCC, in order to investigate the molecular mechanisms underlying the pathogenesis of these hereditary tumors. The results of the miRNA and mRNA integrative analysis indicated that synchronous tumors occurring in the same organ in one individual, and developing from an identical germline background, are molecularly similar even if these renal tumors are of independent clonal origin. These results suggested that the final molecular evolution is not random, and confirmed the \'contingency and convergency\' hypothesis previously described by Fisher *et al* ([@b10-ijo-53-04-1455]). Therefore, it may be hypothesized that VHL-associated tumors harbor the same expression pattern due to loss of the *VHL* gene; however, the difference in global genetic background between the two patients used in the present study allows for the distinction between the different samples of these patients.

The present study demonstrated that miRNA and mRNA expression levels may be used to distinguish VHL-associated renal tumors from sporadic ccRCC. The sporadic ccRCC miRNA signature was similar to ones previously described ([@b14-ijo-53-04-1455],[@b19-ijo-53-04-1455],[@b20-ijo-53-04-1455]). The identified miRNAs were also able to distinguish between high-grade and low-grade ccRCC, as previously reported ([@b21-ijo-53-04-1455]).

In the present study, miR-210 was markedly overexpressed in VHL-associated and sporadic tumors. Overexpression of miR-210 has previously been described in sporadic ccRCC and in several hypoxic tumors ([@b22-ijo-53-04-1455]--[@b24-ijo-53-04-1455]); therefore, its overexpression in VHL-associated RCC is not surprising due to its pseudohypoxic gene signature ([@b25-ijo-53-04-1455]). miR-210 modulates the cellular hypoxic response via a wide range of actions. In particular, miRNA and mRNA profiles of renal VHL-associated tumors are very similar to hypoxic signatures previously reported ([@b26-ijo-53-04-1455]). Another pro-oncogenic pathway was identified through miR-155, which promotes the growth of tumors by targeting *VHL* mRNA ([@b27-ijo-53-04-1455],[@b28-ijo-53-04-1455]) and the activity of hypoxia-inducible factor 1 (HIF1) during prolonged hypoxia ([@b29-ijo-53-04-1455]). Other miRNAs identified in the present study have also been described in the literature, including miR-28-5p, which promotes chromosomal instability in ccRCC by inhibiting mitotic arrest deficient 2 translation ([@b30-ijo-53-04-1455]), or miR-30c-3p (previous ID: miR-30c-2\*) and miR-30a-3p, which inhibit HIF2 activity in ccRCC ([@b31-ijo-53-04-1455]).

An altered metabolic pattern has previously been identified in ccRCC studies ([@b32-ijo-53-04-1455],[@b33-ijo-53-04-1455]). *VHL*, MET proto-oncogene, receptor tyrosine kinase, folliculin, TSC complex subunit 1 (*TSC1*), *TSC2*, fumarate hydratase and succinate dehydrogenase are known as renal cancer-predisposing genes, which are all involved in pathways that respond to metabolic stress or nutrient stimulation. It has previously been suggested that RCC may be regarded as a metabolic disease ([@b34-ijo-53-04-1455]). It may be interesting to perform a metabolic analysis to assess metabolic alterations in ccRCC. It is possible that dysregulated metabolism is fundamental for the occurrence of ccRCC and may provide the basis for the development of novel forms of therapy. In addition, the present study identified numerous upregulated pathways that were associated with the immune system. ccRCC has previously been demonstrated to be immunogenic. Notably, a number of immune cells have been isolated from ccRCC, including natural killer cells, cytotoxic T cells, helper T cells and dendritic cells ([@b35-ijo-53-04-1455]--[@b38-ijo-53-04-1455]). When ccRCC appears as an antigen in the human body, immune activity is induced, leading to a series of enhanced immunization activities. Several genes implicated in these pathways were regulated by the *VHL*/HIF pathway, including C-X-C motif chemokine receptor 4 and stromal cell-derived factor-1α ([@b39-ijo-53-04-1455]). Further studies, in order to obtain an in-depth understanding of the mechanisms implicating the *VHL* gene may be beneficial for the development of novel treatments.

Within the genome, clustering of miRNA genes is common, with 38% of known miRNA genes residing in clusters ([@b40-ijo-53-04-1455]). The present profiling data revealed dysregulation of several miRNA clusters, notably the δ-like non-canonical Notch ligand 1-maternally expressed 3 miRNA cluster (on chromosome 14q32) in all ccRCC samples. Evolutionary conservation of clustered miRNA genes suggests an important common biological function, co-regulating identical targets or components in the same pathway ([@b41-ijo-53-04-1455]). Notably, several miRNAs mapping to 14q32 have been predicted to regulate the same target genes. Loss of expression of this miRNA cluster or other genes in close proximity has previously been reported in ccRCC ([@b42-ijo-53-04-1455]), as well as in other types of cancer ([@b43-ijo-53-04-1455]--[@b45-ijo-53-04-1455]). For example, in osteosarcoma, down-regulation of 14q32 miRNAs stabilizes c-MYC, facilitates apoptotic escape, and sustains tumorigenesis ([@b43-ijo-53-04-1455]). In addition, the MYC pathway is activated in ccRCC and essential for proliferation of ccRCC cells ([@b46-ijo-53-04-1455]). These findings suggested that loss of expression of miRNAs clustered at 14q32 further dysregulates the MYC network and likely contributes to ccRCC development. The 14q32 miRNA cluster members, miR-134 and miR-494, were generally downregulated in nearly all tumors and are described as tumor suppressors in ccRCC cells. miR-134 downregulates cell proliferation and epithelial-to-mesenchymal transition by targeting KRAS proto-oncogene, GTPase ([@b47-ijo-53-04-1455]). A miRNA regulatory balance of oncogenic, metabolic and immune pathways must be struck in ccRCC tumor cells to permit tumor progression. Functional assays and global proteomic analysis are required to better characterize these interaction networks.

In conclusion, from various clonal tumors within the kidney of the same patient, a functional convergence on hypoxic, immune response and metabolism pathways was evidenced, thus contributing to the synchronous oncogenesis of these tumors. Several miRNAs significantly differentially expressed between VHL-related renal tumors and sporadic ccRCC were identified through global miRNA expression profiling, thus suggesting a role for these miRNAs in these tumors. Although further cellular and histological studies are required to determine the precise roles played by these miRNA-mRNA pathways in VHL-associated ccRCC, the present results may help provide a better understanding of these hereditary tumors.
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###### 

Characteristics of tumor samples.

  Tumor number   Hospital    Sex   Age (years)   Histology        Fuhrman\'s grade   Grade class   *VHL* status   microRNA microarray analysis   Gene microarray analysis
  -------------- ----------- ----- ------------- ---------------- ------------------ ------------- -------------- ------------------------------ --------------------------
  First set                                                                                                                                      
  2203_T1        Necker      M     61            VHL-ccRCC        2                  Low           Mutated        Yes                            Yes
  2203_T10       Necker      M     61            VHL-ccRCC        2                  Low           Mutated        Yes                            Yes
  2203_T3        Necker      M     61            VHL-ccRCC        2                  Low           Mutated        Yes                            Yes
  2203_T6        Necker      M     61            VHL-ccRCC        2                  Low           Mutated        Yes                            Yes
  2203_T7        Necker      M     61            VHL-ccRCC        3                  High          Mutated        Yes                            Yes
  2203_T9        Necker      M     61            VHL-ccRCC        2                  Low           Mutated        Yes                            Yes
  1674_T1        Necker      F     39            VHL-ccRCC        3                  High          Mutated        Yes                            Yes
  1674_T11       Necker      F     39            VHL-ccRCC        3                  High          Mutated        Yes                            Yes
  1674_T13       Necker      F     39            VHL-ccRCC        2                  Low           Mutated                                       Yes
  1674_T19       Necker      F     39            VHL-ccRCC        2                  Low           Mutated        Yes                            Yes
  1674_T2        Necker      F     39            VHL-ccRCC        3                  High          Mutated        Yes                            Yes
  1674_T3        Necker      F     39            VHL-ccRCC        3                  High          Mutated        Yes                            Yes
  1674_T4        Necker      F     39            VHL-ccRCC        2                  Low           Mutated        Yes                            Yes
  Second set                                                                                                                                     
  1919           St-Joseph   F     75            Sporadic ccRCC   2                  Low           Wild-type      Yes                            Yes
  2040           Necker      F     45            Sporadic ccRCC   3                  High          Wild-type      Yes                            Yes
  3042           St-Joseph   M     83            Sporadic ccRCC   2                  Low           Mutated        Yes                            Yes
  3503           St-Joseph   M     59            Sporadic ccRCC   4                  High          Wild-type      Yes                            Yes
  3554           St-Joseph   M     47            Sporadic ccRCC   3                  High          Mutated        Yes                            Yes
  3559           St-Joseph   M     61            Sporadic ccRCC   3                  High          Wild-type      Yes                            Yes
  4320           St-Joseph   F     78            Sporadic ccRCC   3                  High          Mutated        Yes                            Yes
  4667           St-Joseph   F     70            Sporadic ccRCC   3                  High          Mutated        Yes                            Yes
  5290           St-Joseph   F     69            Sporadic ccRCC   2                  Low           Mutated        Yes                            Yes
  5668           St-Joseph   M     69            Sporadic ccRCC   2                  Low           Mutated        Yes                            Yes
  5835           St-Joseph   M     60            Sporadic ccRCC   2                  Low           Mutated        Yes                            Yes
  5887           St-Joseph   M     85            Sporadic ccRCC   2                  Low           Mutated        Yes                            Yes
  6517           St-Joseph   M     76            Sporadic ccRCC   2                  Low           Mutated        Yes                            Yes
  6739           St-Joseph   M     53            Sporadic ccRCC   2                  Low           Mutated        Yes                            Yes
  7294           St-Joseph   F     65            Sporadic ccRCC   4                  High          Mutated        Yes                            Yes
  7896           St-Joseph   F     70            Sporadic ccRCC   2                  Low           Mutated        Yes                            Yes
  8527           St-Joseph   F     77            Sporadic ccRCC   2                  Low           Mutated        Yes                            Yes
  9490           St-Joseph   M     67            Sporadic ccRCC   4                  High          Mutated        Yes                            Yes
  9671           St-Joseph   F     45            Sporadic ccRCC   4                  High          Mutated        Yes                            Yes
  40442          St-Joseph   M     56            Sporadic ccRCC   3                  High          Wild-type      --                             Yes
  40815          St-Joseph   M     71            Sporadic ccRCC   3                  High          Wild-type      Yes                            Yes
  40842          St-Joseph   F     77            Sporadic ccRCC   1                  Low           Mutated        Yes                            Yes
  2132           Necker      M     34            VHL-ccRCC        2                  Low           Mutated        --                             Yes
  2920           Bicêtre     M     26            VHL-ccRCC        2                  Low           Mutated        Yes                            Yes
  4573           Bicêtre     M     24            VHL-ccRCC        1                  Low           Mutated        Yes                            Yes
  4734           Bicêtre     M     65            VHL-ccRCC        3                  High          Mutated        Yes                            Yes
  5205           Necker      M     27            VHL-ccRCC        2                  Low           Mutated        Yes                            Yes
  6315           Bicêtre     M     35            VHL-ccRCC        3                  High          Mutated        Yes                            Yes
  6434           Necker      F     40            VHL-ccRCC        2                  Low           Mutated        Yes                            Yes
  6600           Necker      M     23            VHL-ccRCC        2                  Low           Mutated        Yes                            Yes
  7000           Necker      F     45            VHL-ccRCC        2                  Low           Mutated        Yes                            Yes
  8156           Necker      F     40            VHL-ccRCC        2                  Low           Mutated        Yes                            Yes
  8464           Bicêtre     M     28            VHL-ccRCC        2                  Low           Mutated        Yes                            Yes
  50201          Necker      M     31            VHL-ccRCC        3                  High          Mutated        Yes                            Yes

ccRCC, clear-cell renal cell carcinoma; F, female; M, male; VHL, von Hippel-Lindau.

###### 

Dysregulated miRNAs in patients 2203 and 1674.

  miRNA ID                          Patient 2203 vs. normal pool   Patient 1674 vs. normal pool                                             
  --------------------------------- ------------------------------ ------------------------------ --------------- --------- --------------- ---------------
  Common miRNAs                                                                                                                             
  Upregulated                                                                                                                               
  hsa-miR-210                       13.694                         4.119×10^−09^                  1.110×10^−06^   18.204    1.344×10^−09^   9.051×10^−07^
  hsa-miR-155-5p                    6.695                          7.973×10^−06^                  4.130×10^−04^   7.965     2.615×10^−04^   2.887×10^−03^
  hsa-miR-342-3p                    3.389                          1.927×10^−06^                  1.527×10^−04^   3.132     1.483×10^−07^   1.537×10^−05^
  hsa-miR-34a-5p                    3.373                          2.187×10^−04^                  3.983×10^−03^   2.519     7.045×10^−04^   5.858×10^−03^
  hsa-miR-1274a                     2.853                          1.377×10^−04^                  2.995×10^−03^   2.441     3.774×10^−05^   7.159×10^−04^
  hsa-miR-720                       2.773                          9.353×10^−05^                  2.348×10^−03^   2.265     9.233×10^−05^   1.353×10^−03^
  hsa-miR-122-5p                    2.696                          9.032×10^−06^                  4.345×10^−04^   3.808     4.595×10^−05^   8.253×10^−04^
  hsa-miR-150-5p                    2.645                          1.554×10^−04^                  3.271×10^−03^   3.333     7.686×10^−05^   1.204×10^−03^
  hsa-miR-1274b                     2.531                          6.167×10^−04^                  7.416×10^−03^   2.235     1.829×10^−05^   4.663×10^−04^
  hsa-miR-34b-5p                    2.472                          1.131×10^−03^                  1.199×10^−02^   2.239     7.917×10^−05^   1.226×10^−03^
  hsa-miR-106b-5p                   2.463                          8.830×10^−03^                  4.815×10^−02^   2.191     1.354×10^−06^   7.601×10^−05^
  hsa-miR-25-3p                     2.361                          5.440×10^−05^                  1.629×10^−03^   2.343     3.438×10^−07^   2.724×10^−05^
  hsa-miR-93-5p                     2.342                          3.627×10^−05^                  1.164×10^−03^   2.209     1.910×10^−07^   1.838×10^−05^
  hsa-miR-885-5p                    2.059                          7.217×10^−05^                  1.984×10^−03^   2.749     4.733×10^−04^   4.438×10^−03^
  Downregulated                                                                                                                             
  hsa-miR-762                       −2.148                         6.373×10^−04^                  7.597×10^−03^   −2.456    3.143×10^−06^   1.520×10^−04^
  hsa-miR-4270                      −2.167                         1.655×10^−03^                  1.538×10^−02^   −2.318    7.754×10^−06^   2.611×10^−04^
  hsa-miR-218-5p                    −2.259                         1.106×10^−04^                  2.701×10^−03^   −2.030    3.164×10^−03^   1.661×10^−02^
  hsa-miR-30a-3p                    −2.371                         3.591×10^−05^                  1.164×10^−03^   −2.185    6.318×10^−05^   1.051×10^−03^
  hsa-miR-1207-5p                   −2.380                         2.682×10^−03^                  2.101×10^−02^   −2.425    7.777×10^−04^   6.349×10^−03^
  hsa-miR-199a-3p                   −2.382                         5.068×10^−03^                  3.354×10^−02^   −3.405    6.913×10^−03^   3.053×10^−02^
  hsa-miR-188-5p                    −2.474                         3.029×10^−05^                  1.046×10^−03^   −2.172    3.194×10^−06^   1.520×10^−04^
  hsa-miR-30c-5p                    −2.477                         2.188×10^−04^                  3.983×10^−03^   −2.108    3.468×10^−05^   6.970×10^−04^
  hsa-miR-1225-5p                   −2.485                         3.166×10^−03^                  2.331×10^−02^   −2.403    7.302×10^−04^   6.034×10^−03^
  hsa-miR-4286                      −2.487                         1.325×10^−09^                  7.936×10^−07^   −2.279    6.848×10^−08^   1.004×10^−05^
  hsa-miR-30a-5p                    −2.490                         8.286×10^−06^                  4.134×10^−04^   −2.253    5.463×10^−06^   2.230×10^−04^
  hsa-miR-4284                      −2.718                         3.360×10^−03^                  2.446×10^−02^   −4.295    7.493×10^−06^   2.611×10^−04^
  hsa-miR-660-5p                    −2.813                         4.062×10^−05^                  1.244×10^−03^   −2.239    4.978×10^−04^   4.530×10^−03^
  hsa-miR-642b-3p                   −2.863                         3.629×10^−05^                  1.164×10^−03^   −2.775    4.850×10^−08^   1.004×10^−05^
  hsa-miR-135a-5p                   −2.965                         1.202×10^−06^                  1.233×10^−04^   −2.413    3.352×10^−06^   1.520×10^−04^
  hsa-miR-630                       −3.208                         2.354×10^−03^                  1.880×10^−02^   −3.347    3.092×10^−08^   8.330×10^−06^
  hsa-miR-363-3p                    −3.319                         2.369×10^−04^                  4.200×10^−03^   −2.378    1.989×10^−05^   4.871×10^−04^
  hsa-miR-200b-3p                   −3.577                         5.841×10^−05^                  1.684×10^−03^   −2.609    2.844×10^−05^   5.918×10^−04^
  hsa-miR-429                       −3.657                         1.300×10^−04^                  2.917×10^−03^   −2.893    2.199×10^−05^   5.197×10^−04^
  hsa-miR-1202                      −3.772                         6.780×10^−04^                  7.613×10^−03^   −2.993    1.971×10^−03^   1.149×10^−02^
  hsa-miR-141-3p                    −9.901                         1.767×10^−09^                  7.936×10^−07^   −9.272    9.951×10^−07^   5.828×10^−05^
  hsa-miR-200c-3p                   −12.485                        3.817×10^−09^                  1.110×10^−06^   −11.832   9.017×10^−07^   5.784×10^−05^
  Specific miRNAs of patient 2203                                                                                                           
  Upregulated                                                                                                                               
  hsa-miR-21-3p                     2.705                          1.544×10^−05^                  6.710×10^−04^   1.845     1.092×10^−03^   7.619×10^−03^
  hsa-miR-1260b                     2.461                          2.786×10^−04^                  4.750×10^−03^   1.968     1.898×10^−04^   2.265×10^−03^
  hsa-miR-320d                      2.359                          1.634×10^−04^                  1.538×10^−02^   1.756     3.132×10^−03^   1.654×10^−02^
  hsa-miR-181b-5p                   2.339                          4.412×10^−08^                  9.083×10^−06^   1.983     3.519×10^−05^   6.970×10^−04^
  hsa-miR-1260a                     2.261                          6.489×10^−04^                  7.613×10^−03^   1.922     8.246×10^−04^   6.573×10^−03^
  hsa-miR-452-5p                    2.245                          4.431×10^−03^                  3.045×10^−02^   1.382     1.265×10^−02^   4.801×10^−02^
  hsa-miR-130b-3p                   2.243                          1.656×10^−06^                  1.394×10^−04^   1.742     2.452×10^−06^   1.270×10^−04^
  hsa-miR-320e                      2.178                          5.735×10^−04^                  7.087×10^−03^   1.837     2.525×10^−05^   5.755×10^−04^
  hsa-miR-320b                      2.168                          7.956×10^−04^                  8.856×10^−03^   1.714     2.918×10^−04^   3.144×10^−03^
  hsa-miR-342-5p                    2.129                          1.601×10^−05^                  6.741×10^−04^   1.971     1.339×10^−07^   1.503×10^−05^
  hsa-miR-223-3p                    2.056                          2.665×10^−04^                  4.602×10^−03^   1.867     9.326×10^−03^   3.830×10^−02^
  hsa-miR-181a-5p                   2.019                          9.307×10^−04^                  1.011×10^−02^   1.932     1.444×10^−05^   4.052×10^−04^
  Downregulated                                                                                                                             
  hsa-miR-362-3p                    −2.317                         5.680×10^−04^                  7.087×10^−03^   −1.826    2.457×10^−03^   1.385×10^−02^
  hsa-miR-200a-3p                   −2.552                         1.657×10^−04^                  3.433×10^−03^   −1.575    3.224×10^−02^   ns
  hsa-miR-10a-5p                    −3.326                         4.392×10^−04^                  5.915×10^−03^   −1.965    4.617×10^−02^   ns
  Specific miRNAs of patient 1674                                                                                                           
  Upregulated                                                                                                                               
  hsa-miR-142-3p                    2.941                          2.613×10^−02^                  ns              4.372     1.588×10^−03^   9.811×10^−03^
  hsa-miR-489                       1.231                          ns                             ns              3.434     1.139×10^−02^   4.447×10^−02^
  hsa-miR-142-5p                    2.116                          ns                             ns              3.205     1.006×10^−03^   7.348×10^−03^
  hsa-miR-494                       1.975                          1.863×10^−03^                  1.647×10^−02^   2.621     1.116×10^−03^   7.709×10^−03^
  hsa-miR-126-3p                    1.940                          1.606×10^−03^                  1.538×10^−02^   2.191     1.047×10^−04^   1.454×10^−03^
  hsa-miR-15a-5p                    1.569                          ns                             ns              2.187     1.493×10^−05^   4.103×10^−04^
  hsa-miR-15b-5p                    1.045                          1.237×10^−02^                  ns              2.181     1.112×10^−03^   1.488×10^−03^
  hsa-miR-455-5p                    1.230                          ns                             ns              2.096     4.226×10^−05^   7.798×10^−04^
  hsa-miR-140-3p                    1.840                          5.298×10^−04^                  6.796×10^−03^   2.032     1.710×10^−04^   2.105×10^−03^
  hsa-miR-4306                      1.368                          3.099×10^−03^                  2.306×10^−02^   2.005     3.613×10^−04^   3.632×10^−03^
  hsa-miR-185-5p                    1.387                          2.402×10^−02^                  ns              2.005     9.862×10^−04^   7.339×10^−03^
  Downregulated                                                                                                                             
  hsa-miR-4299                      −1.489                         ns                             ns              −2.035    1.415×10^−05^   4.052×10^−04^
  hsa-miR-4254                      −1.879                         3.745×10^−03^                  2.660×10^−02^   −2.081    3.636×10^−06^   1.531×10^−04^
  hsa-miR-204-5p                    −5.917                         2.029×10^−02^                  ns              −2.12     8.344×10^−03^   3.491×10^−02^
  hsa-miR-1268a                     −1.486                         ns                             ns              −2.264    1.260×10^−05^   3.689×10^−04^
  hsa-miR-574-3p                    −1.526                         3.078×10^−02^                  ns              −2.314    9.952×10^−07^   5.828×10^−05^
  hsa-miR-10b-5p                    −1.881                         1.377×10^−02^                  ns              −2.338    8.231×10^−03^   3.463×10^−02^
  hsa-let-7a-5p                     −1.933                         1.263×10^−03^                  1.288×10^−02^   −2.377    1.679×10^−03^   1.014×10^−02^
  hsa-miR-4281                      −1.917                         7.692×10^−03^                  4.525×10^−02^   −2.529    8.819×10^−05^   1.320×10^−03^

miR, microRNA; ns, not significant.

###### 

Summary of major implicated pathways in VHL-associated and sporadic renal tumors.

  KEGG ID                                KEGG description                               KEGG subclass                               KEGG class
  -------------------------------------- ---------------------------------------------- ------------------------------------------- --------------------------------------
  Common pathways in both tumor groups                                                                                              
  hsa04115                               p53 signaling pathway                          Cell growth and death                       Cellular processes
  hsa04510                               Focal adhesion                                 Cellular community                          
  hsa04540                               Gap junction                                                                               
  hsa04060                               Cytokine-cytokine receptor interaction         Signaling molecules and interaction         Environmental information processing
  hsa04514                               Cell adhesion molecules (CAMs)                                                             
  hsa04512                               ECM-receptor interaction                                                                   
  hsa05200                               Pathways in cancer                             Cancers: Overview                           Human diseases
  hsa03320                               PPAR signaling pathway                         Endocrine system                            Organismal systems
  hsa04960                               Aldosterone-regulated sodium reabsorption      Excretory system                            
  hsa04610                               Complement and coagulation cascades            Immune system                               
  hsa04650                               Natural killer cell mediated cytotoxicity                                                  
  hsa04640                               Hematopoietic cell lineage                                                                 
  hsa04672                               Intestinal immune network for IgA production                                               
  hsa04610                               Complement and coagulation cascades                                                        
  hsa04062                               Chemokine signaling pathway                                                                
  hsa04612                               Antigen processing and presentation                                                        
  hsa04621                               NOD-like receptor signaling pathway                                                        
  hsa04660                               T cell receptor signaling pathway                                                          
  hsa04670                               Leukocyte transendothelial migration                                                       
  hsa00532                               Chondroitin sulfate biosynthesis               Glycan biosynthesis and metabolism          Metabolism
  hsa00280                               Valine, leucine and isoleucine degradation     Amino acid metabolism                       
  hsa00380                               Tryptophan metabolism                                                                      
  hsa00330                               Arginine and proline metabolism                                                            
  hsa00260                               Glycine, serine and threonine metabolism                                                   
  hsa00250                               Alanine, aspartate and glutamate metabolism                                                
  hsa00340                               Histidine metabolism                                                                       
  hsa00310                               Lysine degradation                                                                         
  hsa00270                               Cysteine and methionine metabolism                                                         
  hsa00350                               Tyrosine metabolism                                                                        
  hsa00640                               Propanoate metabolism                          Carbohydrate metabolism                     
  hsa00650                               Butanoate metabolism                                                                       
  hsa00620                               Pyruvate metabolism                                                                        
  hsa00020                               Citrate cycle (TCA cycle)                                                                  
  hsa00053                               Ascorbate and aldarate metabolism                                                          
  hsa00010                               Glycolysis/gluconeogenesis                                                                 
  hsa00040                               Pentose and glucuronate interconversions                                                   
  hsa00500                               Starch and sucrose metabolism                                                              
  hsa00630                               Glyoxylate and dicarboxylate metabolism                                                    
  hsa00190                               Oxidative phosphorylation                      Energy metabolism                           
  hsa00910                               Nitrogen metabolism                                                                        
  hsa00071                               Fatty acid metabolism                          Global and overview maps                    
  hsa00072                               Synthesis and degradation of ketone bodies     Lipid metabolism                            
  hsa00140                               Steroid hormone biosynthesis                                                               
  hsa00120                               Primary bile acid biosynthesis                                                             
  hsa00590                               Arachidonic acid metabolism                                                                
  hsa00062                               Fatty acid elongation in mitochondria                                                      
  hsa00830                               Retinol metabolism                             Metabolism of cofactors and vitamins        
  hsa00410                               β-Alanine metabolism                           Metabolism of other amino acids             
  hsa00480                               Glutathione metabolism                                                                     
  hsa00903                               Limonene and pinene degradation                Metabolism of terpenoids and polyketides    
  hsa00982                               Drug metabolism-cytochrome P450                Xenobiotics biodegradation and metabolism   
  hsa00980                               Metabolism of xenobiotics                                                                  
                                         by cytochrome P450                                                                         
  hsa00983                               Drug metabolism-other enzymes                                                              
  Specific to VHL-associated tumors                                                                                                 
  hsa04330                               Notch signaling pathway                        Signal transduction                         Environmental information processing
  hsa00900                               Terpenoid backbone biosynthesis                Metabolism of terpenoids and polyketides    Metabolism
  Specific to sporadic tumors                                                                                                       
  hsa04110                               Cell cycle                                     Cell growth and death                       Cellular processes
  hsa04630                               Jak-STAT signaling pathway                     Signal transduction                         Environmental information processing
  hsa04666                               FcγR-mediated phagocytosis                     Immune system                               Organismal systems
  hsa04662                               B cell receptor signaling pathway                                                          
  hsa04620                               Toll-like receptor signaling pathway                                                       
  hsa01040                               Biosynthesis of unsaturated fatty acids        Lipid metabolism                            Metabolism
  hsa00100                               Steroid biosynthesis                                                                       
  hsa00360                               Phenylalanine metabolism                       Amino acid metabolism                       

VHL, von Hippel-Lindau.

###### 

Dysregulated miRNAs between VHL-associated and sporadic ccRCC samples.

  miRNA ID               Fold-change (VHL/sporadic)   Raw P-value      adj-P-value
  ---------------------- ---------------------------- ---------------- -------------
  Upregulated miRNAs                                                   
  hsa-miR-489            2.267                        0.0103           ns
  hsa-miR-204            2.266                        0.0078           ns
  hsa-let-7f             1.946                        0.0004           0.0123
  hsa-miR-200b           1.914                        0.0012           0.0216
  hsa-let-7a             1.821                        5.8836×10^−05^   0.0036
  hsa-miR-200a           1.767                        0.0035           0.0454
  hsa-miR-146b-5p        1.684                        0.0283           ns
  hsa-miR-429            1.611                        0.0066           ns
  hsa-miR-26b            1.579                        0.0004           0.0121
  hsa-miR-28-5p          1.542                        0.0006           0.0121
  hsa-miR-122            1.527                        0.0347           ns
  hsa-miR-20a            1.521                        0.0002           0.0092
  Downregulated miRNAs                                                 
  hsa-miR-1274a          −1.580                       0.0114           ns
  hsa-miR-1260           −1.727                       0.0027           0.0386
  hsa-miR-886-3p         −1.764                       0.0399           ns
  hsa-miR-1308           −1.812                       0.0136           ns
  hsa-miR-494            −2.882                       6.0369×10^−05^   0.0036
  hsa-miR-923            −4.149                       2.0833×10^−06^   0.0006

miRNA, microRNA; ns, not significant; VHL, von Hippel-Lindau.
